bpc-157 arthritis Would a peptide like BPC 157 help chronic knee pain? BPC-157 Risks for Musculoskeletal Injuries

GH naturally declines beginning in the late 20s and accelerates after 40

Finally, avoid cyanocobalamin

Cancer Research , 64 (11), 37313736

Tirzepatide/Mounjaro Like Semaglutide, these once weekly injections can help lower blood sugar, insulin and cholesterol all of which improves health and longevity

Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability